Cart
sales@molnova.com
Exarafenib
CAS No. 2639957-39-2
Exarafenib( —— )
Catalog No. M35731 CAS No. 2639957-39-2
Exarafenib (RAF/KIN_2787) is a potent, orally available pan-RAF inhibitor with antitumor activity that acts by inhibiting downstream MAPK pathway signaling. It is used in cancer research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 199 | Get Quote |
|
| 5MG | 312 | Get Quote |
|
| 10MG | 534 | Get Quote |
|
| 25MG | 777 | Get Quote |
|
| 50MG | 1003 | Get Quote |
|
| 100MG | 1341 | Get Quote |
|
| 500MG | 2682 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameExarafenib
-
NoteResearch use only, not for human use.
-
Brief DescriptionExarafenib (RAF/KIN_2787) is a potent, orally available pan-RAF inhibitor with antitumor activity that acts by inhibiting downstream MAPK pathway signaling. It is used in cancer research.
-
DescriptionExarafenib (RAF/KIN_2787) is an orally-available, selective pan-RAF inhibitor. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. Exarafenib has anticancer activity.
-
In VitroCell Viability AssayCell Line:Melanoma cell (A375 BRAFV600E, HMVII BRAFG469V; NRASQ61K, WM3629 BRAFD594G; NRASG12D, SKMEL2 NRASQ61R) Concentration:1-10000 nM Incubation Time:24 h Result:Inhibited RAF-dependent melanoma cell line growth.
-
In VivoAnimal Model:BALB/c nude mice xenograft models of BRAF and NRAS-mutant melanoma Dosage:3, 5, 10, 20, 30 mg/kg Administration:Orally; twice daily (BID); 29 days Result:Was effective against BRAFmut & NRASmut human melanoma xenografts in vivo.
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetRaf
-
RecptorRaf | p38 MAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2639957-39-2
-
Formula Weight521.58
-
Molecular FormulaC26H34F3N5O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (191.73 mM; Ultrasonic )
-
SMILESC[C@H](CO)Nc1cc(cc(n1)N1CCOCC1)-c1cc(NC(=O)N2CC[C@@H](CC(F)(F)F)C2)ccc1C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Miller N, et, al. Antitumor activity of KIN-2787, a next-generation pan-RAF inhibitor, in combination with MEK inhibition in preclinical models of human NRAS mutant melanoma.2022 Jun 2;40(16): e15099.
molnova catalog
related products
-
GNE-9815
GNE-9815 is a high kinase-selective inhibitor of RAF and targets KRAS-mutant cancers through combination therapy.
-
Sorafenib-d3
Sorafenib-d3 is a deuterium-labeled Sorafenib which is a multikinase inhibitor(IC50s: 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively).
-
R18
Antagonist of 14.3.3 proteins (KD ≈80 nM). Competitively inhibits 14.3.3-ligand interactions without requiring phosphorylation. Blocks the ability of 14.3.3 to bind to target proteins such as Raf-1, Bad, ASK1 and exoenzyme S.
